An interventional study of Facilitated group therapy with behavioral practice; 18 weeks in Hoarding Disorder, Hoarding and Clutter, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
The proposed study aims to investigate the efficacy of adding in-home decluttering practice to Buried in Treasures Workshop (BIT) facilitated group treatment for hoarding disorder.
Patients participate in Buried in Treasures Workshop (BIT) that has been shown to improve symptoms of hoarding disorder. The investigators hypothesize that adding in-home decluttering practice to the BIT workshop will decrease hoarding symptoms and level of clutter over time.
32 studies on the registry are indexed under Hoarding Disorder; 5 are open to participants now.
This study's enrollment of 41 is above the median of 37 across 28 interventional studies indexed under Hoarding Disorder.
Browse Hoarding Disorder studies →Stanford University is the lead sponsor of 2,168 studies on the registry; 431 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria for Individuals with Hoarding Disorder:
Exclusion Criteria for Individuals with Hoarding Disorder:
Facilitated group therapy with behavioral practice; 18 weeks
Behavioral: Facilitated group therapy with behavioral practice; 18 weeks
Facilitated group therapy with behavioral practice; 18 weeks (after a 18-20 week delay)
Behavioral: Facilitated group therapy with behavioral practice; 18 weeks
Facilitated group therapy for hoarding disorder with behavioral practice
Number of Patients Who Met and Exceeded Response Criteria of the Saving Inventory-Revised (SI-R)
The SI-R is a 23-item questionnaire with 3 sub-scales for difficulty discarding, excessive clutter, and compulsive acquisition. The total score ranges from 0 to 92. The greater the score, the more severe the hoarding symptoms. Total score higher than 41 shows significant difficulty with clutter. For the acquisition subscale, items 2 (reverse score), 9, 11, 14, 16, 18 and 21 are summed together. The subscale ranges from 0 to 28 and score greater than 13 indicates difficulty with excessive acquisition. For the difficulty discarding subscale, items 4(reverse score), 6, 7, 13, 17, 19, 23 are summed together. The subscale ranges from 0 to 28 and score greater than 13 indicates difficulty with discarding. For the clutter subscale, items 1, 3, 5, 8, 10, 12, 15, 20, 22 are summed together. The subscale ranges from 0 to 36 and score greater than 15 indicates difficulty with accumulated clutter. Response was defined as at least a 14 point change (pre-post) in the total score.
Time frame: Change from baseline (pre-treatment) to week 18 (post-treatment) the Immediate Treatment Arm/Group and change from baseline (pre-treatment at 18 weeks) to 36 weeks (post-treatment) for the Delayed Treatment Arm/Group
| Milestone | Immediate Treatment | Delayed Treatment |
|---|---|---|
| Started | 21 | 20 |
| Completed | 18 | 19 |
| Not completed | 3 | 1 |
The SI-R is a 23-item questionnaire with 3 sub-scales for difficulty discarding, excessive clutter, and compulsive acquisition. The total score ranges from 0 to 92. The greater the score, the more severe the hoarding symptoms. Total score higher than 41 shows significant difficulty with clutter. For the acquisition subscale, items 2 (reverse score), 9, 11, 14, 16, 18 and 21 are summed together. The subscale ranges from 0 to 28 and score greater than 13 indicates difficulty with excessive acquisition. For the difficulty discarding subscale, items 4(reverse score), 6, 7, 13, 17, 19, 23 are summed together. The subscale ranges from 0 to 28 and score greater than 13 indicates difficulty with discarding. For the clutter subscale, items 1, 3, 5, 8, 10, 12, 15, 20, 22 are summed together. The subscale ranges from 0 to 36 and score greater than 15 indicates difficulty with accumulated clutter. Response was defined as at least a 14 point change (pre-post) in the total score.
| Participants | Immediate Treatment | Delayed Treatment |
|---|---|---|
| Number of Patients Who Met and Exceeded Response Criteria of the Saving Inventory-Revised (SI-R) | 9 | 13 |
Collected over Baseline (pre-treatment) up to 18 weeks for the Immediate Treatment Arm/Group and up to 36 weeks for the Delayed Treatment Arm/Group. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Treatment | 0/21 (0%) | 0/21 (0%) | 0/21 (0%) |
| Delayed Treatment | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Age, Continuous(years) | Immediate Treatment | Delayed Treatment | Total |
|---|---|---|---|
| Mean | 54.29 ± 12.06 | 58.45 ± 8.41 | 56.37 ± 10.24 |
| Sex: Female, Male(Participants) | Immediate Treatment | Delayed Treatment | Total |
|---|---|---|---|
| Female | 15 | 12 | 27 |
| Male | 6 | 8 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Immediate Treatment | Delayed Treatment | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 6 | 12 |
| Not Hispanic or Latino | 15 | 14 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2016 to primary completion in Jun 2019, 33 months.
Results were first posted in Nov 2025, 6 years 4 months after primary completion.
Of 20 interventional studies with no phase under Hoarding Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 48. This study's 33 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.